Press Releases
All Pfizer published press releases by date and/or category of news
03.14.2023 Vaccines Covid-19 Vaccines Pfizer and BioNTech Receive U.S. Emergency Use Authorization of Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Booster in Children Under 5 Years 03.13.2023 Financial Investments Pfizer Invests $43 Billion to Battle Cancer 03.10.2023 Medicines Pfizer’s ZAVZPRET™ (zavegepant) Migraine Nasal Spray Receives FDA Approval
Media Asset Library
A collection of assets for use by media.
Partnering News
The latest news from Pfizer and its strategic partners
11.10.2022 Corporate Partnerships Fox Chase Cancer Center and Sylvester Comprehensive Cancer Center Collaborate with Pfizer’s Institute of Translational Equitable Medicine to Identify Novel Genetic Drivers of Cancer Disparities in African Ancestry Populations 10.04.2022 Corporate Partnerships Voyager Therapeutics Announces Pfizer License of Next-Generation AAV Capsid for Rare Neurologic Disease Target
Media Contacts
Pfizer Media Relations
We encourage everyone to view our press releases, press statements, and press kits to stay up to date on Pfizer news.
However, to ensure that customers, investors, and others receive the appropriate attention, Pfizer media contacts may only respond to calls and emails from professional journalists.
Media Contacts
General email
[email protected]
United States, Canada and Latin America
+1 212.733.1226
Europe, the Middle East and Africa
+44-(0)173.733.2335
[email protected]
Asia Pacific
+65.918.732.47
What we need
To best help us help you, please be prepared to provide your name and email address, a summary of the article you're working on and your deadline.
Other Frequently Visited Links
For more, see these helpful and often used sections of Pfizer.com
Pfizer Wire
Stay up to date on the latest news and alerts through the Pfizer Wire
Sign up to receive real-time updates on Pfizer’s news from the Pfizer Media Relations team delivered directly to your inbox.